Clinical trial

Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer

NCT05800223

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2023-01-01

PhasePHASE3

Study timeline

Study start (actual)2023-01-01Date precision: day

Registry last updated2023-04-05

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non-small Cell Lung Cancer Metastaticunresolved

Interventions

AlmonertinibDRUG

SBRTRADIATION

Sponsors & collaborators

Shanghai Cancer Hospital, Chinalead sponsor

Mapped research locations

ShanghaiShanghai Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05800223 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.